Genmab A/S has achieved the first sales volume milestone in its DARZALEX (daratumumab) collaboration with Janssen.

The USD 25 million milestone was triggered by sales of DARZALEX reaching USD 500 million in a calendar year. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize DARZALEX.

“We have seen an extremely robust launch of DARZALEX since its approval in the U.S in November 2015 and in Europe in May 2016, with very rapid sales uptake. We are very pleased to receive the first commercial sales volume milestone so quickly,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The milestone payment was included in Genmab’s financial guidance published on December 20, 2016.